In comparison to the OM plus morusin group, inhibiting Nrf2 increased the expression of Runx2, ALP, p21, NQO1, and HMXO‐1, indicating the reversal of morusin's protective effect on VICs (Figure6A–D; Figure S6). The gene discussed is RUNX2; the disease is ocular melanoma.